New-onset atrial fibrillation (AFib) is one of the most common complications after heart surgery, affecting up to 50% of patients and often leading to longer hospital stays, reduced quality of life, and increased risks of stroke, heart failure and death. Researchers at Sarasota Memorial’s Kolschowsky Research and Education Institute are working to address this challenge through participation in the BoxX-NoAF clinical trial, a multicenter international study sponsored by AtriCure.